NCT00574106

Brief Summary

Cancer is the number one killer in Canada and in most countries of the world. The investigators' initial assessment indicates that far infrared radiation has the potential to cure cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
3

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Feb 2008

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 12, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 14, 2007

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2008

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2009

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2009

Completed
Last Updated

August 17, 2009

Status Verified

August 1, 2009

Enrollment Period

1.5 years

First QC Date

December 12, 2007

Last Update Submit

August 14, 2009

Conditions

Neoplasms

Keywords

CancerTumors

Outcome Measures

Primary Outcomes (1)

  • The effect of far infrared radiation on cancerous tumours

    1 year

Secondary Outcomes (1)

  • The effect on far infrared treatment on different kinds of cancer.

    1 year

Study Arms (1)

1

OTHER

Infrared Radiation

Radiation: Far Infrared Radiation

Interventions

Far Infrared RadiationRADIATION

Far Infrared Radiation (5μm to 20μm wavelength)

1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • All cancer patients

You may not qualify if:

  • non-cancer patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Centre for Incurable Diseases

Toronto, Ontario, M4V 1L5, Canada

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Ken Nedd, M.D.

    GAAD Medical Research Institute Inc.

    PRINCIPAL INVESTIGATOR

  • Kwasi Donyina, Ph.D.

    GAAD Medical Research Institute Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 12, 2007

First Posted

December 14, 2007

Study Start

February 1, 2008

Primary Completion

August 1, 2009

Study Completion

October 1, 2009

Last Updated

August 17, 2009

Record last verified: 2009-08

Locations

CA(1)